Anti–tumor necrosis factor (TNF) agents, widely used in rheumatology and gastroenterology, carry some safety risks. While the risk of infection or malignancy are common concerns, neurological complications, while rare, are also possible.
Anti—tumor necrosis factor (anti-TNF) agents, widely used in rheumatology and gastroenterology, carry some safety risks. While the risk of infection or malignancy are common concerns, neurological complications, while rare, are also possible.
During the fourth congress of the European Academy of Neurology, held in Lisbon, Portugal, from June 16 to 19, researchers reported on neurological complications with anti-TNF drugs in their 16 years of experience in a tertiary university hospital in Madrid, Spain.
The researchers performed a retrospective analysis of their center’s neurology department from 2002 to 2007 and identified patients who had received the anti-TNF agents infliximab, etanercept, adalimumab, and golimumab. They included in their analysis patients who had neurological issues while actively being treated with any of these agents.
In total, there were 15 episodes of neurological complications in 14 patients who were receiving treatment with infliximab, adalimumab, or golimumab to treat inflammatory bowel disease, rheumatoid arthritis, spondyloarthropathy, psoriatic arthritis, or pyoderma gangrenosum. No patients being treated with etanercept reported neurological complications.
Nine of the patients who had complications were treated with infliximab, 6 were treated with adalimumab, and 1 was treated with golimumab.
In total:
The authors write that, in their experience, neurological complications of anti-TNF therapies are rare, but that they are most commonly reported with infliximab, and stroke is the most commonly reported complication; “A possible association with stroke of undetermined etiology should be assessed with prospective studies,” say the researchers.
Reference
Gomez A, Nater E, Monreal S, et al. Neurological complications of antiTNF therapies: 16 years of tertiary university hospital experience. Presented at the European Academy of Neurology Congress, June 16-19, 2018; Lisbon, Portugal. Abstract EPR1130. https://ipp-ean18.netkey.at/index.php?p=recorddetail&rid=2dec48c7-efbe-4a30-aa16-a7c040870eb3&t=browsepresentations.
Competitive Pricing in Biosimilars: How Adalimumab Could Shape the Industry
Published: October 29th 2024 | Updated: October 29th 2024Sophia Humphreys, PharmD, MHA, BCBBS, of Sutter Health notes that although initial adoption of adalimumab biosimilars remained low in 2023, competitive pricing pressures have already benefited patients and the health care sector.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Sandoz Report: A Unified Approach to Overcoming Drug Shortages
October 10th 2024A report from Sandoz emphasizes the need for collaboration among stakeholders to eliminate drug shortages impacting over 90% of hospital systems in the US, recommending policy changes and actions to address the ongoing issue, which has caused treatment delays and increased costs.
What AmerisourceBergen's Report Reveals About Payers, Biosimilar Pricing Trends
May 28th 2023On this episode of Not So Different, Tasmina Hydery and Brian Biehn from AmerisourceBergen discussed results from a recent survey, that were also presented at Asembia 2023, diving into the payer perspective on biosimilars and current pricing trends across the US biosimilar industry.
AAM Report: Despite Massive Savings, Patient OOP Costs on Biosimilars, Generics Remain High, Part 2
September 24th 2024Part 2 of our series diving into the Association for Accessible Medicines' (AAM) latest report discusses that while generics and biosimilars saved $445 billion in 2023, their potential is hindered by high patient costs, drug shortages, and ineffective policies, underscoring the need for reforms to fully realize their benefits.
AAM Report: Generics and Biosimilars Savings Reach $445 Billion in 2023, Part 1
September 18th 2024Savings from generic and biosimilar drugs totaled $445 billion in 2023, showing promise for the growth of both markets and highlighting the success of expansion policies for these products, according to a new report from the Association for Accessible Medicines (AAM).